1. P233 Efficacy and safety of once-daily glycopyrronium compared with blinded tiotropium in patients with COPD: the GLOW5 study. (14th November 2013) Authors: Chapman, KR; Beeh, K; Bateman, ED; Beier, J; D'Urzo, AD; Nutbrown, R; Chen, H; Henley, M; Overend, T; D'Andrea, P Journal: Thorax Issue: Volume 68(2013)Supplement 3 Page Start: A182 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P252 Once-daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial. (2nd December 2011) Authors: D'Urzo, A; van Noord, J A; Martin, C; Horton, R; Banerji, D; Lu, Y; Alagappan, V K T; Overend, T Journal: Thorax Issue: Volume 66(2011)Supplement 4 Page Start: A170 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P253 NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24 h: the GLOW1 trial. (2nd December 2011) Authors: D'Urzo, T; Ferguson, G; Martin, C; Alagappan, V K T; Banerji, D; Lu, Y; Horton, R; Overend, T Journal: Thorax Issue: Volume 66(2011)Supplement 4 Page Start: A170 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S50 Once-daily glycopyrronium improves lung function in COPD patients: pooled results of the GLOW1 and GLOW2 studies. (19th November 2012) Authors: Banerji, D; Alagappan, V; Martin, C; He, E; Chen, H; Overend, T Journal: Thorax Issue: Volume 67(2012)Supplement 2 Page Start: A26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗